Granulocyte-colony stimulating factor increases CD123hi blood dendritic cells with altered CD62L and CCR7 expression.
Changes in blood dendritic cell (BDC) counts (CD123(hi)BDC and CD11c(+)BDC) and expression of CD62L, CCR7, and CD49d were analyzed in healthy donors, multiple myeloma (MM), and non-Hodgkin lymphoma (NHL) patients, who received granulocyte-colony stimulating factor (G-CSF) containing peripheral blood stem cell (PBSC) mobilization protocols. Low-dose G-CSF in healthy donors (8-10 microg/kg/d subcutaneously) and high-dose G-CSF in patients (30 microg/kg/d) increased CD123(hi)BDC (2- to 22-fold, mean 3.7 x 10(6)/L-17.7 x 10(6)/L and 1.9 x 10(6)/L-12.0 x 10(6)/L) in healthy donors and MM but decreased CD11c(+)BDC (2- to 10-fold, mean 5.7 x 10(6)/L-1.6 x 10(6)/L) in NHL patients, on the day of apheresis, compared with steady state. After apheresis, CD123(hi)BDC counts remained high, whereas low CD11c(+)BDC counts tended to recover in the following 2-5 days. Down-regulation of CD62L and up-regulation of CCR7 on CD123(hi)BDC were found in most healthy donors and MM patients. CD49d expression was unchanged. Thus, PBSC mobilization may change BDC counts by altering molecules necessary for BDC homing from blood into tissues.
Vuckovic
Slavica
S
Mater Medical Research Institute, South Brisbane, Queensland, Australia.
Kim
Min
M
Khalil
Dailal
D
Turtle
Cameron J
CJ
Crosbie
Georgina V
GV
Williams
Noel
N
Brown
Len
L
Williams
Katrina
K
Kelly
Cathryn
C
Stravos
Penny
P
Rodwell
Robyn
R
Hill
Geoff R
GR
Wright
Susan
S
Taylor
Kerry
K
Gill
Devinder
D
Marlton
Paula
P
Bradstock
Ken
K
Hart
Derek N J
DN
D000328:Adult; D000368:Aged; D001781:Blood Component Removal; D039521:CD11c Antigen / Q000032:analysis; D002452:Cell Count; D003520:Cyclophosphamide / Q000008:administration & dosage; D003713:Dendritic Cells / Q000166:cytology* / Q000276:immunology*; D005260:Female; D016179:Granulocyte Colony-Stimulating Factor / Q000008:administration & dosage / Q000494:pharmacology*; D019650:Hematopoietic Stem Cell Mobilization; D006801:Humans; D053650:Interleukin-3 Receptor alpha Subunit; D019041:L-Selectin / Q000032:analysis*; D008228:Lymphoma, Non-Hodgkin / Q000097:blood / Q000276:immunology; D008297:Male; D008875:Middle Aged; D009101:Multiple Myeloma / Q000097:blood / Q000276:immunology; D054400:Receptors, CCR7; D019707:Receptors, Chemokine / Q000032:analysis*; D016185:Receptors, Interleukin-3 / Q000032:analysis*; D020858:Tissue and Organ Harvesting
C515370:CCR7 protein, human; D039521:CD11c Antigen; C115022:IL3RA protein, human; D053650:Interleukin-3 Receptor alpha Subunit; D054400:Receptors, CCR7; D019707:Receptors, Chemokine; D016185:Receptors, Interleukin-3; D019041:L-Selectin; D016179:Granulocyte Colony-Stimulating Factor; D003520:Cyclophosphamide